Month: January 2026

Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies

Summary: January 25, 2026 news reports AVITA Medical’s 19 abstracts (14 podium) at 2026 Boswick Burn & Wound Symposium, featuring the first surgeon-reported integration of RECELL (autologous cell harvesting for healing), PermeaDerm (temporary coverage with early vascularization/organized tissue), and Cohealyx (wound prep) in single pathways. Cases: Young trauma patient and elderly with large full-thickness wound—PermeaDerm for coverage, Cohealyx prep, RECELL + grafting for closure; reduced dressing changes/follow-ups, potential for community/rural settings. Additional: PermeaDerm trial histology (early vessels, no excess inflammation vs. donor skin); RECELL real-world consistency in healing/complications/hospital stay.

Key Highlights:

• Integration: First combined use for challenging wounds.
• Benefits: Efficient pathway, less frequent interventions.
• Evidence: Histology/clinical trends; full PermeaDerm/Cohealyx results 2026.
• Relevance: Advances regenerative/combined tech for burns/complex wounds.

Read news

Keywords: AVITA Medical, RECELL, PermeaDerm, Boswick Symposium

Packaging failures prompt FDA alert for MediHoney and CVS wound care products

Summary: January 26, 2026 FDA alert from CDRH warns of packaging failures compromising sterility in specific MediHoney Wound and Burn products (all lots of Calcium Alginate Rope/Dressings/Gel) and CVS Wound Gel (lots 2446/2428). Integra LifeSciences reported 11 serious injuries for MediHoney and 3 for CVS as of Dec 19, 2025 (no deaths). Issues stem from production/process controls. Risks: Increased infection from non-sterile use in wounds/burns. Actions: Quarantine/remove/dispose affected products; notify distributors/customers; no additional patient follow-up needed if standard care followed. Integra issued recall notice Jan 16, 2026.

Key Highlights:

• Affected: Multiple MediHoney formats; specific CVS lots.
• Risks: Sterility breach → potential contamination/infection.
• Implications: Reminder of quality vigilance in moist-environment products like honey-based dressings.
• Relevance: Impacts common chronic wound treatments; stresses supply chain safety.

Read article

Keywords: FDA alert, MediHoney, packaging failure, sterility breach

Endocrine and Metabolic Modulation of Vascular Dysfunction in the Diabetic Foot: A Narrative Review

Summary: January 25, 2026 narrative review synthesizes evidence on the endocrine-vascular axis in diabetic foot ulcers (DFUs). Beyond traditional risks (hyperglycemia, dyslipidemia), endocrine alterations (impaired insulin signaling, glucagon excess, adipokine imbalance, stress hormones, thyroid dysfunction) interact with mitochondrial issues and inflammation to impair endothelial function, reduce nitric oxide, promote oxidative stress/pro-ischemic environment, and hinder angiogenesis, ECM remodeling, immune response, and repair. Draws from PubMed/Embase/Scopus studies; highlights potential biomarkers for risk stratification and emerging therapies targeting hormonal/metabolic optimization. Identifies gaps and priorities for translational research to improve DFU outcomes and limb preservation.

Key Highlights:

• Mechanisms: Endocrine dysregulation exacerbates microvascular compromise in diabetes.
• Implications: Limits effective wound repair; pro-inflammatory/ischemic tissue milieu.
• Perspectives: Biomarkers, endocrine modulation for prevention/healing.
• Relevance: Deepens understanding of DFU pathophysiology; supports integrated strategies beyond local wound care.

Read full review

Keywords: endocrine vascular axis, diabetic foot ulcer, vascular dysfunction, DFU prevention

A Season of Reflection and Progress in Wound Management

Summary: December 2025 editorial by John C. Lantis, II, MD, FACS uses the holiday season as a metaphor for reflection, celebration, and new beginnings amid uncertainties in wound care. Highlights progress: increasing stability in tissue/biologic products, shift to online-only journal format, surge in international submissions offering global insights, upcoming consensus documents on debridement across sites and postoperative dehiscence management. Anticipates 18 months of studies on tissue products in DFUs/VLUs, long-term pressure injury outcomes, and atypical wounds. Encourages recharging, engaging with content for better patient understanding (medical/psychological/social), and advancing knowledge to improve lives. Welcomes feedback to enhance article value.

Key Highlights:

• Progress: Biologics stability, international research growth, Wound Care Collaborative Community contributions (image quality, trial designs, PROs).
• Upcoming: Consensus on debridement/dehiscence; studies on healing trajectories, epidemiology.
• Message: Reflect on commitment; reduce suffering, heal wounds, elevate QoL.
• Relevance: Year-end overview tying to synthetic/innovative therapies and global chronic wound challenges.

Read editorial

Keywords: wound management progress, biologic products, debridement consensus, atypical wounds

Evaluation of A Multilayer Antimicrobial Foam Dressing Indicated for Use on Surgical Incisions

Summary: 2025 study (Wounds 37(12):451-455) evaluated Allevyn Ag+ (Smith+Nephew) multilayer antimicrobial foam dressing prophylactically on low-risk surgical incisions (clean/clean-contaminated, ASA 1-3 patients) in orthopedic procedures. Clinician survey (n=54 responses from 8 hospitals) assessed application, conformability, size, adherence, and overall performance via 5-point scale. Key features: ComfortSTAY silicone adhesive (7-day wear, low trauma removal), HighFLEX conformability, ExuLOCK exudate lock, silver foam (1.9-3.0 mg/cm²) for sustained antimicrobial action. Results: 91% ease of application met/exceeded expectations; 70% conformability exceeded; 98% size satisfaction; 89% adherence; 93% overall. 63% rated better than prior dressings; 96% wanted to continue. Conformability highlighted as top benefit for high-motion areas (knee >70%, hip 100%). No objective healing/infection data; clinician opinion-based.

Key Highlights:

• Procedures: 83% orthopedic (knee/hip dominant).
• Performance: High clinician satisfaction; reduced changes via 7-day wear.
• Benefits: Antimicrobial silver, exudate management, minimal pain/trauma on removal.
• Relevance: Prophylactic use in low-SSI-risk incisions; complements post-op care in wound-prone areas.

Read full article

Keywords: Allevyn Ag+, antimicrobial foam dressing, surgical incisions, SSI prevention

The Positive Side of Local Coverage Determination Changes

Summary: Editorial reflects positively on recent updates to Medicare Local Coverage Determinations (LCDs) affecting wound care products and services. Notes improvements such as expanded coverage for cellular/tissue-based products, synthetic matrices, NPWT in outpatient settings, clearer documentation requirements, and reduced prior authorization hurdles in some MAC jurisdictions. Emphasizes how these changes facilitate appropriate use of advanced therapies, support evidence-based practice, decrease denials/delays, and ultimately improve healing rates and quality of life for patients with chronic wounds (VLUs, DFUs, pressure injuries). Encourages providers to stay informed and advocate for continued refinements.

Key Highlights:

• Benefits: Broader access to effective treatments, streamlined billing.
• Impact: Fewer denials, faster initiation of advanced care.
• Call to action: Monitor MAC-specific LCDs and engage in comment periods.
• Relevance: Supports reimbursement for synthetic/innovative products like Mirragen.

Read editorial

Keywords: Local Coverage Determination, LCD changes, wound care reimbursement, advanced therapy coverage

Observational Study: Venous Leg Ulcer Treated with Native Collagen Alginate

Summary: Published observational study evaluates native collagen alginate dressing (e.g., Promogran Prisma or similar) in real-world treatment of venous leg ulcers. Tracks outcomes in patients with recalcitrant VLUs under standard compression therapy + advanced dressing. Key findings include accelerated granulation, reduced wound area over time, decreased pain and exudate levels, fewer dressing changes, and favorable cost-per-healing metrics compared to traditional alginates or gauze. Supports use of collagen-based products to modulate MMPs, promote ECM remodeling, and enhance healing in chronic venous wounds. Emphasizes ease of application and patient tolerance in outpatient/clinic settings.

Key Highlights:

• Outcomes: Faster closure rates, pain/exudate reduction.
• Mechanism: Native collagen binds excess MMPs; alginate manages moisture.
• Real-world: Effective adjunct to compression in hard-to-heal VLUs.
• Relevance: Adds evidence for advanced dressings in venous/chronic care.

Read full study

Keywords: native collagen alginate, venous leg ulcer, observational study, advanced dressing

CMS Field Test Meetings

Summary: January 26, 2026 blog by Dr. Caroline Fife announces or recaps CMS field test meetings (virtual/in-person) focused on wound care-related quality measures, performance indicators, or proposed changes to coverage/determination policies. These sessions allow clinicians, societies, and stakeholders to provide input on draft measures (e.g., healing rates, amputation prevention, documentation standards) before finalization for MIPS, QPP, or LCD updates. Emphasizes importance of participation to shape reimbursement and quality reporting that impacts wound care practices, especially for chronic ulcers, DFUs, and pressure injuries. Includes registration links, agendas, or key discussion points if available.

Key Highlights:

• Purpose: Gather real-world feedback on wound care metrics.
• Topics: Likely healing outcomes, advanced therapy use, prevention benchmarks.
• Call to action: Attend/provide comments to influence policy.
• Relevance: Directly affects coding, coverage (e.g., G2211, advanced products), and practice viability.

Read blog

Keywords: CMS field test, wound care measures, quality reporting, LCD updates

Demystifying Pressure Injury Staging

Summary: This on-demand webinar (free registration) breaks down the standardized staging system for pressure injuries per NPIAP/EPUAP/PPPIA guidelines. Covers definitions and clinical features of Stage 1 (non-blanchable erythema), Stage 2 (partial-thickness loss), Stage 3 (full-thickness loss to fascia), Stage 4 (exposed bone/muscle/tendon), Unstageable (obscured base), Deep Tissue Pressure Injury (persistent non-blanchable deep red/maroon/purple), Mucosal Membrane Pressure Injury, and Medical Device-Related Pressure Injury. Includes visual examples, differential diagnosis (e.g., vs. Kennedy Terminal Ulcer), prevention strategies (risk assessment, offloading, nutrition), and accurate documentation/coding implications for reimbursement and quality metrics. Ideal for nurses, wound specialists, and educators to improve consistency in assessment and reporting.

Key Highlights:

• Stages: Detailed visuals and criteria for each category.
• Special types: Device-related, mucosal, DTI evolution.
• Best practices: Early intervention, photography for tracking, interdisciplinary communication.
• Relevance: Enhances accuracy in pressure injury prevention programs; reduces misclassification risks.

Register/View webinar

Keywords: pressure injury staging, NPIAP guidelines, deep tissue injury, pressure ulcer staging

Marrying Data with Common Sense: Is it Safe to Amputate a Toe at Bedside in an Inpatient Unit?

Summary: January 25, 2026 post (likely by David Armstrong) discusses bedside amputation surgery (BAS) for delimited toe necrosis in diabetic foot units. Cites multi-center study (Feron et al., 2026) showing equivalent 6-month healing (53.8% BAS vs. 52.3% CAS) and re-op rates (24.5% vs. 16.9%). Advocates BAS for ~2/3 suitable cases to reduce delays, keep patients in specialized units, and optimize OR use for complex scenarios. Emphasizes common-sense selection (avoid severe ischemia <2 patent vessels, high CRP/infection); supports #ActAgainstAmputation by enabling faster limb-saving interventions.

Key Highlights:

• Data: Equivalent outcomes BAS vs. OR; no increased risk.
• Benefits: Streamlined care, resource efficiency.
• Limitations: Patient selection critical for success.
• Implications: Shifts paradigm toward bedside in DFU management to minimize major amputations.

Read blog

Keywords: bedside amputation, diabetic foot, toe amputation, ActAgainstAmputation

Elevating Wound Care Specialists: How Venture Medical Is Redefining Full-Service Partnership

Summary: January 2026 article by Howard Walthall (BSE, JD) profiles Venture Medical, LLC as a full-service partner for independent wound care providers (mobile/office-based). Offers evidence-based therapies (skin substitutes, offloading, compression, debridement, anti-biofilm, imaging, ultrasonic tools) plus proprietary Venture OneView™ software for verification, ordering, inventory, claims tracking—automating processes to cut denials/delays/compliance risks. Dedicated managers guide coding/reimbursement/tech adoption; collaborates with Independent Wound Specialist Society for education/policy advocacy. Supports complex chronic wound management (e.g., Medicare patients) by enabling focus on healing over admin burdens.

Key Highlights:

• Ecosystem: Products + tech + logistics + compliance support.
• Software: OneView™ dashboard for efficiency/safety.
• Advocacy: Fair reimbursement, best practices, rural access improvement.
• Relevance: Empowers specialists in advanced/chronic care delivery.

Read full article (subscription may be required)

Keywords: Venture Medical, wound care specialists, reimbursement support, mobile wound care

HMP Global’s Symposium on Advanced Wound Care (SAWC) Announces 2026 Partnership with NPIAP

Summary: Press release highlights enhanced collaboration between HMP Global’s Symposium on Advanced Wound Care (SAWC) and the National Pressure Injury Advisory Panel (NPIAP) for 2026. SAWC Spring | WHS (April 8–12, 2026, Charlotte, NC) offers multidisciplinary CME on emerging science/innovation. NPIAP provides expanded two-day track at SAWC Fall on pressure injury prevention/management, integrating evidence-based guidelines. Registration incentives for both events; aims to advance education, research, interdisciplinary collaboration, and patient outcomes amid rising pressure injury rates.

Key Highlights:

• Events: SAWC Spring (Apr 8-12, 2026, Charlotte); expanded NPIAP track at Fall.
• Focus: Pressure injury best practices, guidelines integration, global platform.
• Benefits: CME, expert sessions, incentives; supports chronic wound community.
• Relevance: Ties to prevention tools/standards in hard-to-heal wounds.

Read press release

Keywords: SAWC 2026, NPIAP partnership, pressure injury, wound care conference

Understanding Standards for Beds and Mattresses: Pressure Care Devices Flammability Safety Criteria

Summary: June 2, 2025 blog from the Society of Tissue Viability reviews flammability and safety criteria for pressure care devices (mattresses, cushions) used in pressure ulcer prevention. Medical devices exempt from domestic furnishings fire regs; key standards include BS 7176 (cigarette/flame/Crib tests), BS ISO 16840-15 (surrogate cigarette test for cushions), and distinctions between ignition resistance/retardancy. Fire retardants pose biocompatibility risks (skin contact concerns). Proposes risk matrix scoring environmental factors (e.g., sprinklers, smoking, oxygen use), user mobility/behavior, and device type to guide selection—low fire risk allows focus on tissue protection; higher risks require trade-offs. Emphasizes clinician procurement based on balanced assessment to minimize both fire hazards and pressure injuries.

Key Highlights:

• Standards: BS 7176/Crib 5/7, BS ISO 16840-15 (NiCr coil test).
• Risks: Noxious gases, post-wash changes; higher in domestic/institutional vs. hospital with suppression.
• Recommendations: Risk matrix for procurement; prioritize pressure relief in low-fire settings.
• Implications: Balances safety for vulnerable patients (elderly, immobile) in wound prevention programs.

Read blog

Keywords: pressure care devices, flammability safety, pressure ulcer prevention, BS 7176

Ostomy Education with The Frank & Lizzie Show: Peristomal Skin Care

Summary: This Demio link directs to a registration page for a live or on-demand webinar/masterclass titled “Ostomy Education with The Frank & Lizzie Show: Peristomal Skin Care.” It features hosts Frank and Lizzie (ostomy/wound care specialists) delivering targeted education on preventing/managing peristomal skin complications—common issues like irritation, dermatitis, leakage, and breakdown that impact quality of life in ostomy patients. Content likely covers assessment, product selection (barriers, pouches, accessories), application techniques, troubleshooting, and evidence-based strategies to maintain healthy peristomal skin. Relevant for wound/ostomy nurses, clinicians, and patients; emphasizes proactive care to reduce revisions, infections, and hospital readmissions. Registration required for access; aligns with broader wound care education trends.

Key Highlights:

• Focus: Peristomal skin health, prevention of common complications.
• Hosts: Frank & Lizzie—experts in ostomy education/show format for engaging delivery.
• Benefits: Practical tools for clinicians/patients; improves adherence/outcomes in chronic ostomy management.
• Relevance: Complements chronic wound care by addressing adjacent peristomal issues in patients with comorbidities (e.g., diabetes, mobility limits).

Register/Access webinar

Keywords: peristomal skin care, ostomy education, Frank Lizzie Show, ostomy complications

Effectiveness of Punch Grafting in Promoting Healing and Reducing Pain in Hard-to-Heal Leg Ulcers

Summary: This single-centre retrospective cohort study (January 2016–December 2024) assessed partial-thickness punch grafting in 93 patients with chronic, hard-to-heal leg ulcers of various etiologies (venous, mixed, arterial, etc.) that remained recalcitrant despite best standard care and treatment of underlying factors. Grafts were harvested from the thigh using 4–6 mm punches, applied to the wound bed, and followed at 1, 3, 6, and 12 months. Primary outcome: complete wound healing. Secondary: pain reduction (via VAS or similar), wound surface area change, donor-site complications, cosmetic outcome, and recurrence. Among 88 analysable patients, 78 (88.6%) achieved full target-ulcer closure by 12 months. Pain improved markedly, with pain-free patients rising from 17.6% at baseline to 76.3% by 6 months. Donor-site issues were rare (6.5%), cosmetic results excellent, and recurrence low (9% within 12 months post-healing). Demonstrates punch grafting as a minimally invasive, effective, durable option for refractory leg ulcers with rapid pain relief and minimal morbidity—providing strong long-term real-world evidence across ulcer types.

Key Highlights:

• Healing rate: 88.6% complete closure of target ulcer at 12 months (78/88 patients).
• Pain relief: Pain-free proportion increased from 17.6% baseline to 76.3% at 6 months; rapid and sustained improvement.
• Safety: Donor-site complications in only 6.5%; excellent cosmetic outcomes at both graft and donor sites.
• Recurrence: Just 9% of healed ulcers recurred within 12 months of closure.
• Relevance: Effective for diverse hard-to-heal leg ulcers (including venous/mixed); minimally invasive alternative to more complex grafts or surgery; supports broader adoption in chronic wound clinics.

Read full article (subscription may be required)

Keywords: punch grafting, hard-to-heal leg ulcers, chronic leg ulcers, wound healing, pain reduction, partial-thickness graft

Plain Radiography for Diagnosing and Monitoring Foot Osteomyelitis in Persons With Diabetes: Accuracy, Limitations and Clinical Utility

Summary: This systematic review evaluates the diagnostic performance of plain radiography (singular and serial) for detecting foot osteomyelitis in people with diabetes—a frequent complication driven by peripheral artery disease, neuropathy, and infection susceptibility. Plain X-rays are low-cost and widely available but suffer from poor sensitivity/specificity. Only one of 14 included studies provided original data on serial radiography. Singular radiography showed highly variable performance (sensitivity 22–93%, specificity 22–94%). Serial radiography achieved 89% sensitivity but only 38% specificity. Across reports, serial imaging improved sensitivity in three studies but showed no specificity advantage in any. Overall, serial radiography offers minimal added benefit over a single radiograph for initial diagnosis or monitoring, though significant research gaps and exclusion bias limit conclusions. Calls for further studies to better define clinical utility in diabetic foot osteomyelitis management.

Key Highlights:

• Diagnostic variability: Singular plain radiography sensitivity/specificity highly inconsistent across studies.
• Serial performance: Higher sensitivity (89%) but poor specificity (38%); outperforms single in sensitivity in only a minority of reports.
• Limitations: Low overall accuracy; early changes often invisible on X-ray (requires 10–14 days for visible bone changes); influenced by comorbidities in diabetes.
• Clinical implications: Plain radiography remains first-line due to accessibility/cost but insufficient alone—often requires MRI, bone scan, or probe-to-bone test for confirmation in suspected diabetic foot osteomyelitis.
• Research gap: Sparse data on serial use; exclusion bias suggests understudied area warrants more prospective research for follow-up monitoring value.

Read full article (subscription may be required)

Keywords: diabetic foot osteomyelitis, plain radiography, serial radiography, diagnostic accuracy, diabetic foot infection

TGF-β-Dependent α11 Integrin Expression Is Reduced in Aging Gingival Wounds

Summary: This study investigates how aging disrupts TGF-β-mediated regulation of α11 integrin—a key collagen receptor essential for fibroblast function and extracellular matrix remodeling—in gingival wound healing. Primary human gingival fibroblasts from young and aged donors showed significantly lower baseline α11 integrin (76% less mRNA, 33% less protein), TGF-β1 (34% less mRNA, 40% less protein), and overall TGF-β activity (38% reduction) in older cells. Exogenous TGF-β1 treatment upregulated α11 integrin mRNA (3.6-fold) and protein (45%) in young fibroblasts but had no effect in aged ones, indicating blunted responsiveness. In vivo, gingival wounds in aged mice exhibited reduced collagen deposition (61%), poorer collagen alignment (48%), lower α11 integrin (77%), and TGF-β1 (86%) compared to young mice. Findings identify diminished TGF-β1 expression and signaling as a key mechanism driving reduced α11 integrin in aging, contributing to impaired connective tissue repair and delayed healing in oral/gingival wounds. Highlights potential therapeutic targets (e.g., TGF-β pathway modulation) to improve wound outcomes in older populations.

Key Highlights:

• Human fibroblasts (aged vs. young): ↓ α11 integrin (mRNA -76%, protein -33%), ↓ TGF-β1 (mRNA -34%, protein -40%), ↓ TGF-β activity (-38%).
• TGF-β1 stimulation: Strong α11 upregulation in young cells (mRNA +3.6×, protein +45%); no response in aged cells.
• In vivo (aged mice wounds): ↓ collagen deposition (-61%), ↓ collagen organization (-48%), ↓ α11 integrin (-77%), ↓ TGF-β1 (-86%).
• Mechanism: Aging impairs TGF-β1-dependent α11 integrin signaling → reduced fibroblast-collagen interaction → poor matrix remodeling/healing.
• Relevance: Explains age-related delays in oral/gingival wound repair; extends to broader aging wound healing deficits (e.g., skin, chronic ulcers); suggests pathway restoration as strategy for elderly patients.

Read full article (subscription may be required)

Keywords: α11 integrin, TGF-β1, aging wound healing, gingival wounds, collagen remodeling, aged fibroblasts

Art and Science of Cellular Therapies (Special Section – Wound Repair and Regeneration)

Summary: This is the Table of Contents page for a themed section/special issue in Wound Repair and Regeneration (ISSN 1524-475X) focused on the “Art and Science of Cellular Therapies” in wound healing. Features peer-reviewed articles on cellular-based innovations (e.g., stem cells, tissue-engineered constructs, matrix products) for repair/regeneration in chronic/acute wounds. Ties directly to future-oriented therapies like synthetic/bioactive matrices (e.g., borate glass scaffolds akin to Mirragen), angiogenesis, and cellular modulation. Full details/paywalled; aligns with broader push for evidence-based advanced biologics/synthetics in hard-to-heal cases.

Key Highlights:

• Theme: Cellular therapies bridging basic science and clinical application.
• Relevance: Covers mechanisms/outcomes for chronic wounds (diabetic, pressure, etc.).
• Context: Journal flagship for wound research; supports RCT/registry evidence needs (cf. USWR white paper).

View TOC

Keywords: cellular therapies, wound repair regeneration, advanced wound healing, matrix products

Pressure Ulcers and Mobile Wound Care – A Winning Combination

Summary: Article/lecture by Zwelithini Tunyiswa (CEO, Open Wound Research) highlights mobile wound care as a pragmatic solution to pressure ulcer challenges, especially in elderly populations with high prevalence and complexity. Delivers specialized interventions directly at point of care (e.g., facilities/homes) for timely management. Emphasizes integration into practice for better patient outcomes, reduced complications, and sustainable economic growth—no specific data/stats, but stresses clinical advantages over traditional settings.

Key Highlights:

• Challenges: Prevalence/complexity of pressure ulcers in elderly.
• Solution: Mobile care for timely/specialized point-of-care treatment.
• Benefits: Improved outcomes; economic sustainability/practice growth.
• Objectives: Describe advantages; implement strategies for chronic wound enhancement.
• Relevance: Supports accessible advanced care in podiatry/chronic settings (e.g., complementing synthetic matrices for hard-to-heal cases).

Read article

Keywords: pressure ulcers, mobile wound care, elderly wound management, podiatry chronic care

Primary Cutaneous Aspergillosis Due to Aspergillus flavus in an Immunocompetent Patient

Summary: Case report of 56-year-old immunocompetent male with chronic facial/right ankle ulcers (2 years) due to primary cutaneous aspergillosis from Aspergillus flavus. Lesions started pruritic, worsened by herbal compresses; diagnosed via culture (green colonies), staining, mNGS. Treated with IV/oral voriconazole + surgical debridement/wound care; healed after 46 days. Rare in immunocompetent; highlights risks in chronic wounds/trauma with contamination (e.g., diabetes/vulnerable populations prone to progression).

Key Highlights:

• Presentation: Pruritic erythema → ulcers with crust/pus; herbal aggravation.
• Diagnosis: A. flavus confirmed; no bacterial co-infection.
• Treatment/Outcome: Antifungal + debridement → gradual healing.
• Relevance: Fungal risks in persistent wounds; early intervention key to avoid systemic spread.

Read full article

Keywords: cutaneous aspergillosis, Aspergillus flavus, chronic ulcer infection, voriconazole

Potential Application of Plant-Derived Extracellular Vesicles in Treatment of Burn Wounds

Summary: Review on plant-derived extracellular vesicles (pEVs) as nano-therapeutics for burn/chronic wounds. Sourced from plants (grapefruit, aloe vera, ginger, lemon, cabbage, etc.); deliver bioactives for anti-inflammatory (↓NF-κB/TNF-α), antioxidant (Nrf2/ROS reduction), pro-healing (proliferation/migration/collagen), pro-angiogenic (↑VEGF/CD31), antibacterial effects. Advantages: safe, non-immunogenic, scalable/cost-effective vs. mammalian exosomes. Evidence from in vitro/in vivo models; potential for diabetic/chronic wounds via similar mechanisms (inflammation control, regeneration).

Key Highlights:

• Sources: Grapefruit, aloe peel, lemon, wheat grass, strawberry, etc.
• Mechanisms: Inhibit cytokines/ROS; promote VEGF, collagen, macrophage reprogramming.
• Advantages: Biocompatible, abundant, eco-friendly production.
• Applications: Burn healing acceleration; extension to diabetic ulcers via oxidative/inflammatory modulation.

Read full article

Keywords: plant-derived EVs, nanovesicles, burn wounds, chronic wound therapy

Prevention and Management of Wound Procedural Pain Management in Adult Patients with Open Wounds

Summary: Review integrates latest evidence on preventing/managing procedural pain in adult open wounds (trauma/chronic, e.g., dressing changes/debridement). Pain affects 76-95% patients, delays healing/compliance. Recommends routine assessment (VAS/NRS), education, moist/low-adhesion dressings, gentle cleansing/debridement, WHO ladder pharmacology, non-pharm (distraction, TENS, iontophoresis), prophylactic analgesia, multidisciplinary tailoring. High-quality evidence for standardized techniques; moderate for adjuncts.

Key Highlights:

• Assessment: VAS/NRS pre/during/post-procedure.
• Techniques: Moist dressings, saline for adhesion, low-tack adhesives to avoid MARSI.
• Interventions: WHO ladder; non-pharm (VR/distraction, TENS); prophylactic use (<30% currently).
• Relevance: Critical for chronic wounds with frequent procedures/sensitivity.

Read full article

Keywords: wound procedural pain, pain management, dressing changes, prophylactic analgesia

Research on the Role of Autophagy in Vascular Endothelial Cells in the Healing of Chronic Refractory Wounds

Summary: January 13, 2026 review explores autophagy in vascular endothelial cells (VECs) during chronic refractory wound healing, especially diabetic wounds. Autophagy (mainly macroautophagy) activated by ischemia/hypoxia/inflammation/infection maintains homeostasis, clears damage, supports angiogenesis via VEGF, reduces ROS/apoptosis/inflammation. Dysregulation (excessive or inhibited) delays healing in diabetes. Evidence from in vitro/in vivo models; potential therapies target pathways (e.g., PI3K/Akt/mTOR) or TCM ointments (MEBO, comfrey) to regulate autophagy for better vascular regeneration and healing.

Key Highlights:

• Mechanisms: LC3-II/Beclin-1 upregulation; pathways PI3K/Akt, PINK/Parkin, MAPK/ERK.
• Benefits: Promotes VEGF, angiogenesis; anti-inflammatory (↓TNF-α/IL-6); anti-apoptotic (Bcl-2/Caspase-8).
• Diabetes context: Hyperglycemia impairs VECs; autophagy mitigates ROS, enhances paracrine effects.
• Therapeutics: Modulate for VEGF secretion, inflammation control; TCM plasters promising but need precision.

Read full article

Keywords: autophagy, vascular endothelial cells, diabetic wound healing, angiogenesis

Autologous Millifat Grafting as a Reconstructive Strategy for Complex Lower Limb Defects in a Diabetic Patient After Necrotizing Fasciitis

Summary: Article page accessible but insufficient relevant content extracted (possible paywall, rendering issue, or minimal text). Focuses on a case using autologous millifat grafting (micronized fat) for reconstructing complex lower limb defects following necrotizing fasciitis in a diabetic patient—likely highlighting regenerative benefits, volume restoration, and healing in challenging diabetic wounds post-infection/debridement. Implications for autologous fat-based reconstruction in chronic/traumatic limb defects.

Read full article

Keywords: millifat grafting, necrotizing fasciitis, diabetic limb defects, autologous reconstruction

CAMPs Wound Care Summit 2026 – Home Page

Summary: The third annual CAMPs Wound Care Summit (hosted by Journal of Wound Care) returns March 6–7, 2026, at Hilton West Palm Beach, Florida, as a live in-person event. Focuses on Cellular, Acellular, and Matrix-Like Products (CAMPs) for wound management—covering clinical innovations, regulatory landscape, advances in wound care, and adjuvant therapies. Builds on 2025 success (350+ delegates, top researchers/KOLs, physicians, surgeons, scientific/commercial leaders). Emphasizes engaging program development; resort-style venue with modern amenities, dining, shopping, pool. Call to action: Register now and book discounted rooms.

Key Highlights:

• Event: Live, March 6-7, 2026; Hilton West Palm Beach, FL.
• Topics: CAMPs innovations, regulations, clinical evidence, adjuvants.
• Audience: Researchers, clinicians, industry leaders in advanced wound products.
• Relevance: Ties directly to synthetic/matrix-like breakthroughs (e.g., bioactive scaffolds like Mirragen) for hard-to-heal wounds.

Register/Visit site

Keywords: CAMPs, wound care summit, cellular acellular matrix, advanced wound products

Kennedy Terminal Ulcer: How It Differs From Preventable Pressure Injuries

Summary: January 9, 2026 article explains Kennedy Terminal Ulcer (KTU) as an unavoidable skin injury signaling external skin failure from internal physiologic decline during the dying process (e.g., reduced circulation, nutrition, organ shutdown). Named after Karen Lou Kennedy (observed 1983), it appears rapidly (hours to days) despite optimal care, unlike preventable pressure injuries caused by prolonged/intense pressure/shear on bony prominences or devices. Overlap possible, but KTU tied to terminal/multi-organ failure; emphasizes palliative/hospice focus on comfort (gentle care, minimal repositioning) over aggressive healing, with documentation showing attentive interventions adjusted for tolerance. Addresses family concerns about “neglect” by clarifying systemic etiology and emotional support needs.

Key Highlights:

• Onset/Appearance: Sudden (hours/overnight; “3:30 Syndrome”); pear-shaped, butterfly-shaped, irregular; deep purple/maroon/red/yellow/black discoloration; rapid progression.
• Location: Typically sacrum/coccyx (lower back near tailbone).
• Preventability: Unavoidable due to dying process/skin failure; not from correctable pressure—interventions can’t outpace decline.
• Differences: Pressure injuries preventable via repositioning/support surfaces/nutrition; KTU signals terminal decline, comfort-focused care (pain/moisture management, as-tolerated turning).
• Documentation/Implications: Shows care remained attentive; hospice prioritizes QoL; diagnostic uncertainty common, overlaps with deep tissue injury descriptions (NPIAP staging).
• Historical: First described by Karen Kennedy; referenced in NPIAP/CMS guidelines on unavoidable ulcers.

Read full article

Keywords: kennedy terminal ulcer, KTU, skin failure, end-of-life wound, palliative wound care, pressure injury

Association between WeChat-based remote care guidance and diabetic foot ulcer healing: a retrospective cohort study

Summary: PeerJ retrospective cohort (2021–2022, follow-up to 2024; n=131 DFU patients): WeChat-based remote guidance (education, image assessment, MDT consultations) as adjunct to standard care significantly improved healing (88.1% vs. 63.9%; HR=2.27), faster times, QoL, and satisfaction. Stronger effects in moderate ulcers (Wagner 2–3) and interventional cases; supports mHealth for self-management in resource-limited settings.

Key Highlights:

• Healing: 88.1% intervention vs. 63.9% control (P=0.001).
• Subgroups: High HR in Wagner 2–3 (up to 34.2) and post-procedure.
• Benefits: Improved QoL/satisfaction; high engagement via text/video/interactive.
• Relevance: Effective remote tool for chronic DFU management/healing acceleration.

Read full article

Keywords: WeChat remote care, DFU healing, mHealth, Wagner grade

Association between WeChat-based remote care guidance and diabetic foot ulcer healing: a retrospective cohort study

Summary: PeerJ retrospective cohort (2021–2022, follow-up to 2024; n=131 DFU patients): WeChat-based remote guidance (education, image assessment, MDT consultations) as adjunct to standard care significantly improved healing (88.1% vs. 63.9%; HR=2.27), faster times, QoL, and satisfaction. Stronger effects in moderate ulcers (Wagner 2–3) and interventional cases; supports mHealth for self-management in resource-limited settings.

Key Highlights:

• Healing: 88.1% intervention vs. 63.9% control (P=0.001).
• Subgroups: High HR in Wagner 2–3 (up to 34.2) and post-procedure.
• Benefits: Improved QoL/satisfaction; high engagement via text/video/interactive.
• Relevance: Effective remote tool for chronic DFU management/healing acceleration.

Read full article

Keywords: WeChat remote care, DFU healing, mHealth, Wagner grade

High Mortality Following Major Amputation in Diabetes: An Analysis of Risk Factors and Causes of Death (2024)

Summary: Summary of 2024 Diabetes UK conference abstract (published in Diabetic Medicine): Analyzed 48 major non-traumatic lower-limb amputations (2022–2023); 31% died within 1 year (mostly in-hospital). Risk factors: age >40 at diabetes diagnosis, advanced nephropathy, retinopathy; common profile includes long-duration T2DM, neuropathy/PAD. Causes: cardiorespiratory (40%), sepsis (DFU-related 13%, unrelated 20%). Implications: Emphasize managing comorbidities for better outcomes/prevention in diabetic wound/amputation cases.

Key Highlights:

• Mortality: 31% at 1 year; similar for BKA/AKA.
• Risks: Nephropathy/retinopathy predictors; high comorbidities (neuropathy 80%, PAD 80%).
• Causes: Cardiorespiratory dominant; sepsis notable.
• Amputation reasons: Ischaemia (56%), sepsis/gangrene (36%).

Read summary

Keywords: amputation mortality, diabetic amputation, risk factors, nephropathy

8-10pc of Diabetic Patients Develop Foot Ulcer Complications

Summary: January 10, 2026 post highlights diabetic foot ulcer risks: 8-10% of diabetic patients affected, leading to permanent disability if untreated. Pakistan has high diabetes burden (one in four affected, third globally). Stresses uncontrolled blood sugar as key risk; prevention via early screening, regular checks, lifestyle changes. Announces inauguration of Diabetic Foot Clinic at Dow University of Health Sciences (DUHS) for specialized care, with plans for state-of-the-art upgrade—no direct AI/advanced wound ties, but supports multidisciplinary prevention focus.

Key Highlights:

• Stats: 8-10% develop ulcers; high prevalence in Pakistan.
• Risks: Disability, pregnancy complications in gestational diabetes.
• Prevention: Early screening, blood sugar control, lifestyle.
• Innovation: New DUHS Diabetic Foot Clinic for intervention.

Read post

Keywords: diabetic foot ulcer, diabetes prevalence, foot clinic, prevention

Proposal: Wound Improvement AI Indicator Should Be Developed

Summary: January 11, 2026 blog post proposes developing an Affordable Smartphone-Based Wound Improvement Indicator (WII%) for objective, quantifiable tracking of wound healing in chronic/acute cases (e.g., diabetic foot ulcers, pressure sores, burns). Uses budget Android phones with on-device lightweight AI for metrics like size, tissue quality, color/inflammation, edges, moisture—computing signed % improvement/deterioration. Addresses subjective assessments, high burden in India, and access gaps; seeks collaboration (e.g., IIT Bombay) for pilots and scale-up to enable early detection, remote monitoring, reduced visits, and amputation prevention in high-risk populations.

Key Highlights:

• WII%: Weighted average % change across parameters (clinician-configurable, e.g., higher weight on tissue/inflammation for DFUs).
• Tech: On-device AI, calibration sticker for scale/color, flash consistency, blur checks; relative changes for skin tone bias.
• Benefits: Affordable, explainable, home-care suitable; alerts for worsening; builds Indian wound dataset.
• Relevance: Targets DFUs/chronic wounds for early intervention in resource-limited areas.
• Next: Collaboration/pilots (200–400 wounds), grant prep (DST/BIRAC/ICMR).

Read proposal

Keywords: wound AI, WII%, smartphone wound tracking, diabetic foot ulcer, remote monitoring

Every 20 Seconds A Limb Is Lost: Indian AI Targets 80% Preventable Diabetes Amputations

Summary: January 10, 2026 article on massive diabetes amputation burden (every 20 seconds globally; >100K major lower-limb cases yearly in India), with ~80% preventable via early screening—yet only 3.5% get full foot exams. Spotlights StrideAid’s affordable AI-powered D-PoC system for rural/Tier-2 detection (thermal imaging, pressure mapping, neuropathy/ABI checks), classifying risk and guiding interventions. Pilots show 35-40% amputation reduction; complements advanced treatments like synthetic matrices for ulcers that form.

Key Highlights:

• Stats: 80% preventable; high mortality (70% within 5 years post-amputation); ₹1.5L DFU cost.
• Tool: D-PoC AI (20-min screening, risk profiling, multilingual StrideGPT).
• Outcomes: 35-40% amputation drop in targeted areas; >8,500 screenings.
• Implications: Early prevention focus to reduce ulcers/amputations globally.

Read article

Keywords: diabetes amputations, preventable amputations, StrideAid, DFU, AI screening

CLOTS: Head To Toe

Summary: Upcoming non-accredited conference (January 17–18, 2026, Orlando, FL) advances thromboembolic care through expert insights, guidelines, innovations (AI/tech), and hands-on workshops. Covers clot pathophysiology, VTE/stroke management, multidisciplinary teams—indirectly relevant to wound care via vascular/perfusion issues in chronic wounds (e.g., diabetes/PAD-related ulcers).

Key Highlights:

• Focus: Clots head-to-toe, evolving treatments, team-based care.
• Innovations: AI/emerging tech in thromboembolic management.
• Audience: Vascular/wound specialists for improved outcomes.

Event details

Keywords: thromboembolic, VTE, vascular wound, clots

Analysis of Bias Criteria Checklist for Wound Care Registries & EHRs

Summary: The 2019 USWR white paper argues chronic wounds (affecting ~15% Medicare patients, up to $96.8B annual costs) are symptoms of systemic issues with high comorbidities—making RCT evidence unrepresentative. It promotes registry-based real-world data for evaluating advanced therapies (biologicals/synthetics) in real patients, introducing the ABCs checklist to minimize biases in observational studies. Supports unbiased assessment of products like synthetic matrices in heterogeneous populations.

Key Highlights:

• Burden: 8.2M Medicare patients; surgical dehiscence/common “no-name” wounds prevalent.
• Thesis: Registries > RCTs for real-world efficacy; USWR as QCDR since 2014.
• ABCs Checklist: Addresses selection/information/channeling/analytical bias via transparent reporting.
• Implications: Enables comparative effectiveness for advanced wound care in comorbid cases.

Download white paper

Keywords: real-world evidence, chronic wounds, US Wound Registry, bias checklist, advanced therapies

Coding When Caring for a Complex Condition

Summary: This August 2024 blog explains proper use of HCPCS G2211 as an add-on to office/outpatient E&M codes for longitudinal management of a single serious or complex condition (e.g., chronic diabetic ulcers/wounds). It details eligibility, documentation requirements, and examples tied to podiatric/chronic wound scenarios, stressing accurate billing to reflect complexity without standalone use or with modifier 25. Relevant for practices using advanced therapies in ongoing care—no Mirragen specifics, but supports reimbursement for complex wound visits.

Key Highlights:

• G2211: Add-on for E&M when visit is part of ongoing/comprehensive care for complex condition.
• Examples: Chronic ulcer management in diabetes, with complications like nerve damage.
• Documentation: Note longitudinal role, changing needs, and complexity impact on care.
• Restrictions: No use with modifier 25; base E&M level first.
• Implications: Enhances billing accuracy for repeated wound evaluations/treatments.

Read coding guide

Keywords: G2211, E&M coding, chronic ulcer, diabetic wounds, podiatry billing

What’s Evolving in Podiatric Dermatology: Research and Tools to Elevate Practice

Summary: This September 2025 article reviews emerging research and practical tools in podiatric dermatology to improve diagnosis/treatment of common foot conditions. It covers topical efinaconazole efficacy for onychomycosis (especially in older adults/with gel polish), Brannock device for detecting subtle foot length discrepancies causing nail trauma, nailfold videocapillaroscopy (NVC) for early microvascular changes in diabetes (linked to nephropathy), and potential HPV involvement in recalcitrant intractable plantar keratosis (IPK). Emphasizes noninvasive, integrated approaches bridging dermatology, biomechanics, and systemic care for better outcomes in podiatric practice—no direct mention of Mirragen or synthetic matrices, but highlights need for advanced tools in diabetic foot complications.

Key Highlights:

• Onychomycosis: Efinaconazole 10% achieves higher cure rates in >65 age group; compatible with gel polish.
• Nail trauma: Brannock device identifies half-size differences for better footwear prevention of retronychia/pincer nails.
• Diabetes microvascular: NVC detects early capillary changes (tortuosity, comma-shaped) as noninvasive systemic marker.
• IPK: HPV DNA in persistent cases suggests antiviral options like cryotherapy/laser.
• Practice elevation: Multidisciplinary, early intervention focus for adherence and holistic foot health.

Read full article

Keywords: onychomycosis, efinaconazole, diabetic microvascular, nailfold videocapillaroscopy, IPK, podiatric dermatology

Management of Wounds of Various Aetiologies With Technology Lipido-Colloid Mesh With Silver Sulphate (TLC-Ag) Dressing

Summary: Combined case series (n=9 various wounds) and multicenter study (n=728) evaluated TLC-Ag dressing. Infection signs ↓72%; healed/improved 92%; pain-free changes, good aesthetics. Effective across DFUs, VLUs, PIs, surgical; silver sulphate antimicrobial with lipido-colloid for atraumatic removal.

Key Highlights:

• Outcomes: 92% healed/improved; infection ↓72%.
• Comfort: Pain-free changes; good periwound skin.
• Aetiologies: DFU, VLU, PI, surgical, burns.
• Authors: Not specified in summary.

Read article

Keywords: TLC-Ag, silver sulphate, various aetiologies, infection reduction

The Role of Artificial Intelligence in Wound Care: Applications, Evidence and Future Directions

Summary: Comprehensive review of AI in wound care: imaging analysis (92% accuracy bacterial detection), risk prediction (75-93% PI/DFU recurrence), smart dressings (sensor-integrated), telehealth monitoring. Evidence: high concordance with experts, faster assessments, reduced errors. Challenges: data bias, validation; future: personalized algorithms, integrated systems, ethical frameworks.

Key Highlights:

• Applications: Imaging, prediction, dressings, telehealth.
• Evidence: 92% bacterial accuracy; 75-93% risk prediction.
• Benefits: Faster, objective, remote care.
• Future: Personalized, bias-mitigated, regulatory standards.
• Authors: Not specified in summary.

Read review

Keywords: AI wound care, imaging, prediction, smart dressings, telehealth

Chronic Oedema in the Lower Limb: Practical Guidance on Diagnosis, Effective Treatment and Ongoing Management

Summary: EWMA position document provides practical guidance for chronic lower limb oedema: pathophysiology (lymphatic/venous/phlebolymphoedema), differential diagnosis, conservative/compression therapy (gold standard), skin/wound care, clinical pathways, patient perspectives, epidemiology/economics. Emphasizes early intervention, multidisciplinary care for VLUs/DFUs with oedema.

Key Highlights:

• Pathophysiology: Lymphatic failure, venous insufficiency.
• Treatment: Compression core; skin care, exercise.
• Pathways: Structured diagnosis/management.
• Economics: High burden; early treatment cost-effective.

Read guidance

Keywords: chronic oedema, lower limb, compression, diagnosis, EWMA

Progressive Mobility to Promote Healing of a Stage 4 Sacral Pressure Injury in a Patient With Spinal Cord Injury

Summary: Case: 49F obese with stage 4 sacral PI, deconditioned/non-adherent. Multidisciplinary: WOC nurse debridement/dressings, structured PT program with seating system. Progressive sitting tolerance ↑ to 4 hours daily; PI volume ↓92%. Demonstrates mobility as adjunct for healing in SCI patients.

Key Highlights:

• Patient: Obese, SCI, non-adherent.
• Intervention: PT + custom seating.
• Outcomes: 92% volume reduction, daily 4-hour sitting.
• Authors: Not specified in summary.

Read case

Keywords: progressive mobility, sacral PI, SCI, seating

Modified Masquelet Technique With Resorbable Antibiotic Cement and Biologic for DFU Osteomyelitis

Summary: Case: 75M DFU with hallux osteomyelitis; joint excision, resorbable vancomycin-calcium sulfate spacer + amniotic allografts/synthetic matrix. Weekly monitoring; full closure 9 weeks, no recurrence; patient underwent kidney transplant post-healing. Demonstrates modified Masquelet with resorbable materials/biologics for infected bone defects in DFUs.

Key Highlights:

• Procedure: Spacer + biologics; weekly changes.
• Outcomes: Closure 9 weeks; no recurrence.
• Comorbidity: Successful transplant post-healing.

Read case

Keywords: modified Masquelet, resorbable cement, DFU osteomyelitis, amniotic allograft

OMO Bath: A Cost-Effective Enzymatic Wound Debridement Method in Resource-Limited Settings

Summary: Case series (n=4 large septic chronic wounds, Uganda) used OMO detergent enzyme bath (15-30 min daily): rapid necrotic tissue removal, granulation promotion, prepared for grafting/healing. Cost $1.50-2.10/month vs hundreds for commercial enzymes/surgery. Safe, no allergies; suitable for extremities in LMICs.

Key Highlights:

• Wounds: Large septic; 3-20 sessions.
• Efficacy: Necrotic removal, granulation, graft-ready.
• Cost: <$2/month; accessible LMICs.
• Safety: No adverse reactions.
• Authors: Not specified in summary.

Read case series

Keywords: OMO bath, enzymatic debridement, LMICs, cost effective, granulation

What to Do When Patients Drop Your Doctor Title

Summary: Discusses common issue of patients addressing physicians (particularly women) by first name, reflecting implicit bias and undermining authority. Impacts rapport, respect; strategies: polite correction (“Please call me Dr.”), model from staff, ally support. Highlights gender disparity in medicine.

Key Highlights:

• Issue: First-name address erodes professionalism.
• Disparity: More frequent for women physicians.
• Strategies: Gentle correction, staff modeling.
• Impact: Strains patient-physician relationship.

Read article

Keywords: doctor title, gender bias, patient communication

Successful Treatment of Moderately Ischaemic DFUs Using Intermittent Topical Oxygen

Summary: Post-hoc analysis of RCT (n=moderate ischaemia DFUs) showed intermittent topical oxygen (TWO2) achieved 39% complete healing at 12 weeks vs 0% sham (p<0.0076). Multimodal mechanism: oxygenation, cyclical compression, humidification. Home-use device; suggests efficacy in ischaemic DFUs traditionally challenging for adjuncts.

Key Highlights:

• Healing: 39% vs 0% at 12 weeks.
• Mechanism: Oxygen + compression + humidity.
• Device: Portable home-use.
• Authors: Not specified in summary.

Read analysis

Keywords: topical oxygen, ischaemic DFU, TWO2, healing rates

Staged Limb Salvage in Diabetic Foot Infection: A Case Report

Summary: Case: 53M T2DM/pyelonephritis developed necrotizing fasciitis foot. Staged: emergent debridement, electrospun synthetic fiber matrix + NPWT, delayed STSG. Sepsis resolved; >95% graft take; ambulation by 6 weeks post-graft. Demonstrates staged approach with synthetic adjuncts for complex infected DFUs.

Key Highlights:

• Progression: Pyelonephritis → necrotizing fasciitis.
• Staged: Debridement → matrix/NPWT → STSG.
• Outcomes: Full closure, ambulation 6 weeks post-graft.
• Authors: Not specified in summary.

Read case

Keywords: staged salvage, necrotizing fasciitis, synthetic matrix, NPWT, DFU

Ten Top Tips: Surgical Release and Splinting of Burn Scar Contractures

Summary: Practical guide for burn scar contracture management: prevention (early therapy/silicone), surgical timing (6-12 months), techniques (Z-plasty for bands, full-thickness grafts), intra-op splinting, post-op rehab (ROM day 5-7, massage). Emphasizes multidisciplinary OT input, custom anticontracture orthoses 23h/day x 6 months, family education for compliance.

Key Highlights:

• Prevention: Early excision, therapy, silicone/compression.
• Surgical: Z-plasty bands, full-thickness grafts defects.
• Splinting: Custom thermoplastic day 0, 23h/day.
• Rehab: Active ROM early, monitor pressure sores.
• Authors: Ahmed Emam, Sarah Gardner et al.

Read tips

Keywords: burn contractures, surgical release, splinting, Z-plasty, compliance

January 21st Webinar: Open for Registration

Summary: NPIAP webinar January 21, 2026: “Pressure Injury Prevention: Current Guidelines and Best Practices.” Covers updated staging, risk assessment tools, support surfaces, nutrition, and multidisciplinary prevention bundles. Free registration; 1 CE credit available.

Key Highlights:

• Date: Jan 21, 2026; virtual.
• Topics: Staging, risk tools, bundles, nutrition.
• CE: 1 credit.
• Registration: Open to all.

Register

Keywords: NPIAP webinar, pressure injury, prevention, guidelines

Non-BLA Skin Substitute Wastage Payment Change

Summary: APMA alerts members: Effective January 1, 2026, CMS will not reimburse wastage for non-BLA skin substitutes; only administered units billable (JW/JZ modifiers not applicable). BLA products exempt. Providers must select appropriate product sizes to avoid waste; impacts DFU/VLU treatment planning and inventory.

Key Highlights:

• Effective: Jan 1, 2026.
• Scope: Non-BLA substitutes; no wastage payment.
• Exception: BLA products.
• Advice: Optimize sizing; review inventory.

Read release

Keywords: CMS wastage, non-BLA, skin substitutes, 2026, APMA

ACFAS 2026 Annual Scientific Conference

Summary: The 84th ACFAS Annual Scientific Conference is scheduled for Las Vegas: pre-conference February 23, main February 24-26, post-conference February 27, 2026. Focuses on advanced foot/ankle surgical education, research presentations, and networking for podiatric surgeons. No specific agenda yet, but typically includes DFU management, reconstructive techniques, and wound care sessions.

Key Highlights:

• Dates: Feb 23-27, 2026; Las Vegas.
• Format: Pre/main/post-conference tracks.
• Target: Podiatric surgeons, residents, researchers.
• Expected: CME credits, abstracts, exhibits.

Conference page

Keywords: ACFAS 2026, foot ankle, Las Vegas, podiatric surgery

Medical Device-Related Pressure Injury: What Wound Care Teams Need to Know

Summary: Comprehensive guide to medical device-related pressure injuries (MDRPI): device-shaped ulcers from sustained pressure/shear (masks, tubes, collars). Risks: patient (immobility/edema), device (rigid/tight), care (delayed checks). Prevention bundles: structured assessments, prophylactic silicone foams, microclimate control, repositioning, interprofessional input (RT/nursing/PT). Emerging: infrared/ultrasound for subclinical detection. Incidence highest ICU; bundles ↓ 30-50%.

Key Highlights:

• Risks: Patient/device/care factors; ICU highest.
• Bundles: Inspections under devices, foams, offloading.
• Roles: RT fit, nursing monitor, PT position.
• Tech: Infrared/ultrasound early detection.
• Outcomes: Bundles ↓ incidence 30-50%; education key.

Read full guide

Keywords: MDRPI, pressure injury, prevention bundles, device interfaces, interprofessional

Use of Hypothermically Stored Amniotic Membrane on Diabetic Foot Ulcers: A Multicentre Retrospective Case Series

Summary: Multicenter retrospective (n=50 DFUs) evaluated hypothermically stored amniotic membrane (HSAM) + SOC. 78% complete closure by week 12 (median 55 days); >60% area reduction in 96%; mean 5.5 applications (interval 7.5 days). From presentation to baseline: -68.3% area. Positive outcomes suggest HSAM accelerates healing, reduces financial burden/QoL impact in DFUs.

Key Highlights:

• Closure: 78% week 12; median 55 days.
• Reduction: >60% area in 96%; -68.3% pre-baseline.
• Applications: Mean 5.5; 7.5-day interval.
• Patients: 68% male, mean age 66.7, area 3.5 cm².
• Authors: Not specified in summary.

Read case series

Keywords: HSAM, DFU, amniotic membrane, retrospective, healing rates

Dehydrated Human Amnion/Chorion Membrane to Treat Venous Leg Ulcers: A Cost-Effectiveness Analysis

Summary: Markov model (3-year horizon, Medicare perspective) compared dHACM following parameters for use (FPFU: initiated 30-45 days post-diagnosis, weekly/biweekly) vs no advanced treatment (NAT) for VLUs. dHACM dominated: -$170 per-patient costs, +0.010 QALYs; NMB $1178 ($100k/QALY threshold). Cost-effective 63% PSA simulations. Recurrence rates key uncertainty driver; supports dHACM reimbursement for qualifying VLUs.

Key Highlights:

• Outcomes: Cost-saving + QALY gain → dominance.
• NMB: $1178 favor dHACM.
• PSA: 63% cost-effective at $100k threshold.
• Model: 4-state Markov; real-world data.
• Authors: Not specified in summary.

Read analysis

Keywords: dHACM, VLU, cost-effectiveness, Markov, Medicare

The Effect of Beta-Glucan on Wound Healing: A Systematic Review and Meta-Analysis

Summary: Systematic review/meta-analysis (4 studies: 2 RCTs, 2 cohorts; n=644) evaluated topical beta-glucan for wounds. Chronic wounds: OR 2.14 for healing at 12 weeks (p<0.01, I²=0%); sustained benefits to 24 weeks. Acute wounds (burns): no significant epithelization time reduction (MD -1.70 days, p=0.25). Beta-glucan promotes immune activation/tissue repair in chronic; inconclusive for acute. Calls for more RCTs to standardize/confirm.

Key Highlights:

• Chronic: OR 2.14 (2x healing 12 weeks); low heterogeneity.
• Acute: No benefit (high heterogeneity).
• Studies: 2 chronic (likely DFU), 2 acute (burns).
• Limitations: Few studies, heterogeneity.
• Authors: Not specified in summary.

Read full meta-analysis

Keywords: beta-glucan, wound healing, meta-analysis, chronic wounds, acute wounds

Patients’ and Caregivers’ Satisfaction With Virtual Wound Care Services in Saudi Arabia

Summary: Cross-sectional survey (n=4190: 2300 patients, 1890 caregivers) assessed virtual wound care satisfaction in Saudi Arabia (April-Dec 2024). Patients reported significantly higher satisfaction (mean 51.29, 66.3% high) than caregivers (33.3% high, 62.8% low). Patients rated voice/visual quality, comfort, courtesy higher; caregivers concerned accessibility/communication. Factors: younger age, male, higher education, employment, positive health perception ↑ satisfaction. Recommends targeted caregiver support/training for equitable telehealth.

Key Highlights:

• Satisfaction: Patients 66.3% high vs caregivers 33.3%.
• Reuse/Recommend: Patients higher agreement.
• Factors: Demographics/health perception influence.
• Barriers: Caregiver accessibility/communication.
• Authors: Not specified in summary.

Read full study

Keywords: virtual wound care, satisfaction, Saudi Arabia, patients, caregivers

Innovations in Diagnostics, Treatment and Delivery of Care: Advancing the Wound Care Toolkit

Summary: Editorial reviews Volume 33 Issue 4 innovations: POCUS early gas gangrene detection in DFU enabling prompt intervention; NPWT+STSG for TB dehiscence/fistula (95% healing); beta-glucan meta-analysis (2x healing rates chronic wounds); virtual wound care high patient satisfaction in Saudi Arabia (caregiver concerns); silicone gel sheeting reduces hypertrophic scar pain/severity. Highlights advancing toolkit for better outcomes in complex/chronic wounds.

Key Highlights:

• POCUS: Early gas gangrene detection.
• NPWT+STSG: 95% healing TB dehiscence.
• Beta-glucan: 2x healing chronic wounds.
• Virtual Care: High patient satisfaction.
• Silicone: ↓ scar pain/severity.

Read editorial

Keywords: innovations, POCUS, beta-glucan, virtual care, silicone gel

Enhanced Wound Healing of Deep Wound Dehiscence and Fistula in Abdominal Tuberculosis, With Negative Pressure Wound Therapy and Split-Thickness Skin Graft

Summary: Evidence-based case report of 54-year-old man with abdominal TB post-surgery developing deep dehiscence (10×5 cm) and enterocutaneous fistula. NPWT applied twice over 10 days reduced pain, wound size (8×5 cm), promoted granulation, and closed fistula. STSG performed day 16 post-NPWT; 95% healing at 20 days post-graft (5% minor necrosis/infection). Total healing time 46 days. Demonstrates NPWT + STSG efficacy for complex TB-related abdominal wounds, enhancing granulation/fistula closure.

Key Highlights:

• Patient: 54M, abdominal TB, post-op day 7 dehiscence/fistula.
• NPWT: 10 days → fistula closed, granulation, size ↓.
• STSG: Day 16 post-NPWT; 95% take at 20 days.
• Outcomes: Pain ↓, no major complications.
• Authors: Muhammad Farhan, Muhammad Iqbal, Muhammad Asif Rashid et al.

Read case report

Keywords: NPWT, STSG, abdominal TB, dehiscence, fistula, Muhammad Farhan

Patient, Disability and Clinician Groups Condemn CMS “Dangerous Experiment” With Ostomy, Urological, and Tracheostomy Supplies

Summary: WOCN and allied patient/disability/clinician groups issued a joint statement condemning CMS’s November 28, 2025, final DMEPOS rule fast-tracking ostomy, tracheostomy, and urological supplies into Medicare Competitive Bidding Program as early as 2026. Groups call it a “dangerous experiment” ignoring warnings: supplies are life-sustaining prosthetics needing individual tailoring, not commodities; bidding slashes choice to mail-order contractors, overriding clinicians; risks leaks, infections, hospitalizations; Congress protected these items—CMS circumvents administratively. Urge immediate halt, collaboration for targeted fraud solutions without harming access.

Key Highlights:

• Rule: Adds supplies to bidding; ignores stakeholder warnings.
• Risks: Leaks/infections/hospitalizations; loss of choice/clinical override.
• Criticism: Undermines CMS principles; shifts costs to ERs/clinics.
• Call: Halt implementation; work with patients/clinicians/Congress.
• Signatories: WOCN + patient/disability groups.

Read full statement

Keywords: CMS supplies, competitive bidding, ostomy, urological, WOCN

CMS Announces New Skin Substitute Payment Methodology: Possible Next Steps

Summary: CMS finalized a volume-weighted average payment of **$127.28 per square centimeter** for most 361 HCT/P skin substitute products under Medicare Part B (non-facility and HOPD) starting 2026, based on Q4 2024 ASP data. This addresses rapid payment growth; section 351 biologicals retain ASP methodology. No impact on WISeR model or DFU/VLU LCDs. Many current payment limits fall below $127.28, potentially affecting product availability; providers should review CMS ASP Pricing Files to compare HCPCS limits and guide selection.

Key Highlights:

• Rate: $127.28/cm² volume-weighted ASP (Q4 2024).
• Scope: Part B non-facility/HOPD; separate application reimbursement.
• Exceptions: Section 351 biologicals use ASP.
• Next Steps: Download latest ASP file from cms.gov; check Column D limits vs $127.28.
• Implications: Viability check for products; non-Medicare payers may follow.

Read full blog

Keywords: CMS skin substitutes, 2026 payment, flat rate, ASP, DFU VLU